产品
编 号：F741168
分子式：C24H21ClFNO4
分子量：441.88
分子式：C24H21ClFNO4
分子量：441.88
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1346705-53-0
产品详情
生物活性：
DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
体内研究：
DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性。Animal Model:MV411 mouse xenograft model
Dosage:30 mg/kg
Administration:Oral administration, twice daily for 21 days
Result:Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
体外研究：
DHODH-IN-23 (Compound A; 72 h) 抑制急性髓系白血病细胞增殖。DHODH-IN-23 (0.1-3 μM; 72 h) 诱导 THP-1 细胞中 CDllb 的表达。
DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
体内研究：
DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性。Animal Model:MV411 mouse xenograft model
Dosage:30 mg/kg
Administration:Oral administration, twice daily for 21 days
Result:Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
体外研究：
DHODH-IN-23 (Compound A; 72 h) 抑制急性髓系白血病细胞增殖。DHODH-IN-23 (0.1-3 μM; 72 h) 诱导 THP-1 细胞中 CDllb 的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备